Global Antimicrobial Resistance Diagnostics Market Size, Share, and Forecast Analysis 2025-2029

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

What Are the Antimicrobial Resistance Diagnostics Market Size Forecast for 2025?
The market size of antimicrobial resistance diagnostics has significantly expanded over the past few years. The market is projected to increase from $4.10 billion in 2024 to $4.41 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The substantial growth during the historic period can be credited to factors such as the escalating instances of hospital-based infections, misuse of antibiotics among humans and animals, the growing threat of multi-drug resistant organisms, increased public health monitoring initiatives, and a rise in diagnostic tests for infectious diseases.

What Is the Market Size Outlook for Antimicrobial Resistance Diagnostics Until 2029?
Predictions show substantial growth for the antimicrobial resistance diagnostics market in the coming years. It's estimated that by 2029, the market will rise to $5.82 billion, experiencing a compound annual growth rate (CAGR) of 7.2%. The surge during the forecasted period is anticipated due to the increasing demand for swift diagnostic tools, heightened consciousness of antimicrobial stewardship, an upturn in government funding for tracking resistance, growing application of point-of-care testing, and the escalating requirement for early infection detection. The estimated period will also likely see technological progression in diagnostic platforms, advancements in resistance gene detection methods, increased investments in research and development, the production of portable testing devices, and breakthroughs in multiplex and high-throughput testing.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

What Are the Major Factors Driving Demand in the Antimicrobial Resistance Diagnostics Market?
The increase in drug-resistant infections is projected to spur growth in the antimicrobial resistance diagnostics market. These infections occur when microorganisms such as bacteria, viruses, fungi or parasites adapt to drugs that were once effective against them, resulting in standard treatments becoming ineffective and making infections more challenging to control. The overuse of antibiotics in agriculture, especially the routine addition of low-dose antimicrobials to animal feed, is the primary reason for the escalating prevalence of drug-resistant infections, as it promotes resistance that can transfer to humans via the food chain. Diagnostic tools for antimicrobial resistance, like rapid genetic assays and culture-based sensitivity tests, are crucial in battling the increasing incidence of drug-resistant infections because they allow for early detection of resistant pathogens, facilitate targeted treatments, and help curb the wrongful use of wide-spectrum antibiotics. For example, the UK Health Security Agency (UKHSA) reported in November 2023 that the total cases of antibiotic-resistant infections in England grew from 55,792 in 2021 to approximately 58,224 in 2022, indicating a yearly increase of 4% in antimicrobial resistance across the country. As a result of this increasing prevalence of drug-resistant infections, the antimicrobial resistance diagnostics market is witnessing significant growth.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

How Are End-Use Segments Shaping the Antimicrobial Resistance Diagnostics Market Outlook?
The antimicrobial resistance diagnostics market covered in this report is segmented -

1) By Product Type: Kits And Reagents, Instruments And Consumables
2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens
3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies
4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:
1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media
2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

What Are the Strategic Trends Transforming the Antimicrobial Resistance Diagnostics Market Landscape?
Focusing on the creation of innovative products like multiplex polymerase chain reaction (PCR) assays which can detect multiple pathogens and resistance genes at once, the leading companies in the antimicrobial resistance diagnostics market are striving to improve diagnostic precision and efficiency. By using several sets of primers in a single reaction to identify diverse DNA targets, this method greatly diminishes the consumption of time and resources. For instance, in May 2022, Vela Diagnostics, a molecular diagnostics company based in Singapore, introduced the PathoKey MP urinary tract infections (UTI) ID and antimicrobial resistance (AMR) PCR Test. This product aids in the simultaneous detection of 14 UTI pathogens and 14 antimicrobial resistance genes and offers both automated and manual workflows. It also delivers test results in a minimal time of four hours for swift, lab-scale AMR profiling. The PathoKey MP UTI ID & AMR PCR Test aims to provide clinical labs with speedy, high-volume detection abilities for guiding prompt intervention and effective antibiotic treatment.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Who Are the Prominent Companies in the Antimicrobial Resistance Diagnostics Market by ?
Major companies operating in the antimicrobial resistance diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Seegene Inc., Alifax S.r.l., Accelerate Diagnostics Inc., Lumos Diagnostics Holdings Pty Ltd, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc., OpGen Inc., T2 Biosystems, Jiangsu Medomics Medical Technology Co. Ltd.

Which Region Is Expected to See the Highest CAGR in the Antimicrobial Resistance Diagnostics Market?
North America was the largest region in the antimicrobial resistance diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.